

**KURZPROTOKOLL**  
**TIGER-Optune**

<b>Öffentlicher Titel</b>	TumortheraPIefelder bei neu diagnostizierten Glioblastomen
<b>Wissenschaftl. Titel</b>	The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care – TIGER Study
<b>Kurztitel</b>	TIGER-Optune
<b>Studienart</b>	multizentrisch, prospektiv, offen/unverblindet, einarmig, nicht-interventionelle Studie
<b>Studienphase</b>	nicht zutreffend
<b>Erkrankung</b>	Nervensystem: Gliome: Glioblastom (WHO Grad IV) - Erstlinie
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Newly diagnosed histologically confirmed GBM (WHO-Grade IV)</li><li>- Patient within first 3 cycles of first-line tumor-specific maintenance chemotherapy</li><li>- Clinical indication for TTFields treatment</li><li>- Given informed consent for use and processing of data</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Present or planned pregnancy</li><li>- Significant additional neurological disease (e.g. significantly increased intracerebral pressure (ICP) with a significant midline shift of the brain)</li><li>- Active implanted medical device (e.g. deep brain stimulator)</li><li>- Documented allergy to conductive hydrogel</li><li>- Skull defect (e.g. missing bone with no replacement, bullet fragments in the skull)</li></ul>
<b>Alter</b>	18 Jahre und älter
<b>Prüfzentren</b>	<b>Universitätsklinikum Frankfurt</b> (Nachbeobachtung) Dr. Senckenbergisches Institut für Neuroonkologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Bianca Diehl Tel: 069 6301-87711 Fax: 069 6301-87713 <a href="mailto:bianca.diehl@unimedizin-ffm.de">bianca.diehl@unimedizin-ffm.de</a>
<b>Sponsor</b>	Novocure GmbH
<b>Registrierung in anderen Studienregistern</b>	ClinicalTrials.gov NCT03258021